A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis
NATIONAL CANCER INSTITUTE
· United States · $10M USD
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.